Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

Roche has licensed global rights to Alector's AL050, a preclinical brain-penetrant engineered glucocerebrosidase enzyme replacement therapy for Parkinson's disease, for up to $1.27bn, including $100m upfront and up to $1.17bn in milestone payments. AL050 uses Alector's blood-brain barrier delivery platform, Alector Brain Carrier, and targets GCase deficiency, a driver of neurodegeneration. Roche's Genentech will handle development, manufacturing and commercialisation across all indications, while Alector retains ownership of the ABC platform.